DNA疫苗市场按应用、技术平台、递送方式、给药途径、研发阶段和最终用户划分－2025年至2032年全球预测

预计到 2032 年，DNA 疫苗市场规模将达到 8.6867 亿美元，复合年增长率为 14.09%。

关键市场统计数据
基准年 2024	3.0254亿美元
预计年份：2025年	3.4445亿美元
预测年份 2032	8.6867亿美元
复合年增长率 (%)	14.09%

引言概述了正在重塑全球DNA疫苗研发的新科学动能、递送技术创新和战略意义。

在核酸疗法整体和递送技术改进的推动下，DNA疫苗的科学和商业性进程已进入严格检验和选择性推进阶段。儘管DNA疫苗历来因其理论优势（热稳定性、易于设计以及能够编码复杂抗原）而备受推崇，但由于递送效率低和人体免疫抗原性不足，其广泛应用受到限制。近年来，质体工程、线性及微环DNA平台以及对先天免疫调控机制更深入理解的进步，重新激发了研发人员、资助者和临床研究人员的兴趣。

技术、临床策略和相关人员行为的变革性变化正在加速DNA疫苗的实际应用和策略合作。

DNA疫苗领域正经历一场变革，其驱动力主要来自三个相互交织的因素：技术进步、临床检验趋势以及相关人员不断变化的期望。分子支架和载体设计的进步拓展了能够在体内稳定表达的抗原构建体的种类，而线性DNA和微环平台的出现则为研发人员提供了在表达效率和生产便捷性之间进行权衡的新选择。同时，电穿孔、脂质奈米颗粒和聚合物奈米颗粒等递送方式的改进显着降低了传统上有效活化免疫反应的障碍。

2025年关税趋势和贸易政策调整将如何影响供应链策略、采购重点和製造地区域化决策

2025年关税调整和贸易政策调整的累积影响，进一步加剧了支持DNA疫苗研发和生产的全球供应链的复杂性。质体和线性DNA生产所需的关键原料——包括专用酵素、层析法树脂、一次性生物製程组件和试剂级耗材——极易受到跨境成本波动的影响。在关税导致投入成本上升或采购不确定性增加的地区，发起公司和合约研发生产机构（CDMO）正透过重新评估筹资策略、扩大库存缓衝以及与当地供应商建立合作关係来稳定采购前置作业时间，从而应对这一挑战。

关键细分洞察揭示了应用重点、平台选择、管理方法、临床阶段和最终用户趋势将如何影响专案策略和商业化计划。

基于细分市场的洞察揭示了不同适应症、技术平台、给药方式、给药途径、研发阶段和最终用户所对应的独特研发路径和商业性考虑。在应用领域方面，针对感染疾病（感染疾病为细菌感染、寄生虫感染和病毒感染疾病）的项目往往优先考虑快速免疫诱导、低温运输耐受性和扩充性。同时，专注于骨髓恶性肿瘤和固态肿瘤的肿瘤计画则优先考虑抗原特异性、合併免疫疗法策略和肿瘤微环境调控。平台选择（线性DNA、微环DNA或质体DNA）会影响生产复杂性、有效载荷能力和基因组安全性认知，进而影响监管互动和合作伙伴选择。

提供切实可行的区域性见解，阐释美洲、欧洲、中东和非洲以及亚太地区在监管、製造业和医疗保健体系方面的差异如何影响专案策略。

区域观点影响着不同市场中开发商和投资者的策略重点，这些市场拥有不同的法规结构、医疗基础设施和生产能力。在美洲，强大的资本市场和创新型的法规环境促进了早期临床试验和公私合营，而集中的製造群支持快速规模化生产和垂直整合的供应链。同时，欧洲、中东和非洲地区（EMEA）是一个异质性环境，监管协调工作与多样化的准入途径和采购机制并存，迫使申办方制定灵活的临床开发计划和支付方参与策略，以反映当地的报销实际情况。

关键的企业级洞察，阐述了平台创新者、临床阶段生物技术公司、大型製药合作伙伴和合约研发生产机构 (CDMO) 如何整合自身能力，加速 DNA 疫苗的研发进程。

DNA疫苗领域的企业组成既有竞争又有合作，涵盖了专业平台开发商、临床阶段生物技术公司、大型製药合作伙伴以及契约製造组织（CMO）。平台开发商致力于透过分子设计、专有递送佐剂或生产流程的创新来降低生产成本并提高表达效率，从而实现差异化竞争。临床阶段生物技术公司则倾向于专注于适应症范围较窄的领域，在这些领域，差异化的免疫学特征或生物标记组合能够加速概念验证。同时，大型製药企业则倾向寻求策略合作和许可，以完善其现有的疫苗产品组合和分销能力。

为行业领导者提供实用建议，以优先考虑管理创新、供应链韧性、监管策略、合作伙伴关係和客製化商业化方案。

产业领导者可以采取一系列切实有效且影响深远的倡议，在降低风险的同时，加速产品研发和商业化进程。首先，优先投资于能够显着改善抗原表现和提高患者耐受性的递送技术和给药途径，并使这些投资与目标适应症和最终用户需求相符。其次，透过对多家供应商进行资质认证、探索区域製造伙伴关係以及将关税和贸易应急预案纳入筹资策略，增强供应链合格，避免专案中断，并确保进度按计划进行。

本研究采用的调查方法结合了文献综述、法规审查、专家咨询和供应链分析。

这项高阶主管级分析所依据的研究结合了对同侪审查文献、临床试验註册库、监管指导文件和已发表技术报告的系统性回顾，并辅以有针对性的专家咨询。研究对科学和临床发现进行了三角验证，以确保临床前检验、给药方式表现和临床开发模式的一致性。透过分析近期关税表、官方贸易公告和供应链中断案例研究，检验了贸易和政策影响，重点在于采购和生产决策如何即时调整。

总之，我们将技术进步、营运需求和区域因素综合起来，共同确定了 DNA 疫苗产生影响的路径。

总之，DNA疫苗正从一个主要停留在理论层面的可能性转变为现代免疫疗法和预防策略中不可或缺的一部分。平台工程的进步，以及递送和给药方法的显着改进，正在扩大DNA疫苗的适应症范围，使其更具竞争力。同时，贸易政策趋势和区域环境的差异等外部因素，要求对生产、采购和打入市场策略进行周密的规划。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• DNA疫苗奈米颗粒和电穿孔递送系统的进步提高了临床试验中的免疫抗原性。
• 政府和私人部门加大投资将加速DNA疫苗平台的研究和商业化进程。
• 开发耐热质体製剂，以减少全球DNA疫苗分发对低温运输的依赖性
• 利用新型抗原辨识和高通量定序技术开发的个人化癌症DNA疫苗的出现
• 生技公司与大型製药公司达成策略性授权协议，加速DNA疫苗研发管线扩张
• 人类DNA疫苗候选药物在主要市场获得监管核准以应对新兴感染疾病的里程碑
• 透过将先进的佐剂系统与质体DNA构建体整合，增强细胞和体液免疫反应。
• 扩大工业质体生产製程规模，以满足全球对DNA疫苗临床试验日益增长的需求

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 DNA疫苗市场按应用领域划分

• 感染疾病
  • 细菌感染疾病
  • 寄生虫感染疾病
  • 病毒感染疾病
• 肿瘤学
  • 骨髓恶性肿瘤
  • 固态肿瘤

9. 按技术平台分類的DNA疫苗市场

• 线性DNA
• 迷你环状DNA
• 质体DNA

第十章 DNA疫苗市场依递送方式划分

• 电穿孔
• 基因癌症
• 奈米颗粒递送
• 针头注射

第十一章：DNA疫苗市场依给药途径划分

• 皮内给药
• 肌肉内注射
• 鼻腔
• 皮下注射

第十二章 DNA疫苗市场依研发阶段划分

• I期临床试验
• II期临床试验
• III期临床试验
• 商业的
• 临床前

第十三章 DNA疫苗市场（依最终用户划分）

• 诊所
• 医院
• 研究所

第十四章 DNA疫苗市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章 DNA疫苗市场（按类别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国DNA疫苗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Inovio Pharmaceuticals, Inc.
  • GeneOne Life Science, Inc.
  • VGXI, Inc.
  • Zydus Cadila Ltd.
  • GenScript Biotech Corporation
  • Applied DNA Sciences, Inc.
  • Entos Pharmaceuticals, Inc.
  • Takis Biotech Srl
  • Vical, Inc.
  • Merck & Co., Inc.

The DNA Vaccine Market is projected to grow by USD 868.67 million at a CAGR of 14.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 302.54 million
Estimated Year [2025]	USD 344.45 million
Forecast Year [2032]	USD 868.67 million
CAGR (%)	14.09%

Introduction framing the renewed scientific momentum, delivery innovations, and strategic implications that are reshaping DNA vaccine development globally

The scientific and commercial narrative for DNA vaccines has entered a phase of intensified scrutiny and selective momentum, prompted by broader nucleic acid therapy progress and refined delivery science. Historically, DNA vaccines were celebrated for their theoretical advantages-thermostability, ease of design, and capacity to encode complex antigens-but adoption was constrained by delivery inefficiencies and suboptimal immunogenicity in humans. Recent advances in plasmid engineering, linear and minicircle DNA platforms, and a more nuanced understanding of innate immune modulation have reignited interest among developers, funders, and clinical investigators.

Consequently, technology maturation is converging with pragmatic clinical strategy. Electroporation and nanoparticle-based carriers are demonstrating improved antigen expression and immune priming in trial settings, and intradermal and intramuscular administration routes are being optimized to balance safety with immunologic potency. On the regulatory front, clearer guidance on vector characterization and manufacturing controls is facilitating more predictable development pathways. Taken together, these dynamics are reshaping the risk calculus for both established biologics companies and nimble biotech entrants, creating an environment in which strategic partnerships, targeted investments in delivery technologies, and curated clinical programs are central to realizing the long-promised utility of DNA vaccines.

Transformative shifts in technologies, clinical strategies, and stakeholder behavior that are accelerating DNA vaccine viability and strategic collaboration

The DNA vaccine landscape has experienced transformative shifts driven by three interlocking forces: technological refinement, clinical validation trends, and evolving stakeholder expectations. Advances in molecular scaffolding and vector design have expanded the repertoire of antigen constructs that can be reliably expressed in vivo, and the emergence of linear DNA and minicircle platforms is offering developers alternative trade-offs in expression efficiency and manufacturing simplicity. In parallel, improvements in delivery modalities such as electroporation and lipid- or polymer-based nanoparticles are materially reducing prior barriers to robust immune activation.

Clinical development strategies have also shifted toward combination approaches that pair DNA vaccines with adjuvants, heterologous prime-boost regimens, or checkpoint modulators in oncology. As a result, trial designs are increasingly adaptive and biomarker-driven, with a heavier emphasis on correlates of protection and immune durability. Moreover, the competitive landscape is adapting: long-term players are recalibrating portfolios to incorporate DNA vaccines where they complement existing modalities, while smaller innovators are focusing on niche indications or platform differentiation. These shifts collectively push the field toward pragmatic collaboration, targeted regulatory engagement, and selective capital deployment that prioritize demonstrable clinical value and manufacturable delivery solutions.

How evolving tariff dynamics and trade policy adjustments in 2025 are reshaping supply-chain strategies, procurement priorities, and manufacturing localization decisions

The cumulative impact of tariff changes and trade policy adjustments in 2025 has introduced additional complexity into global supply chains that underpin DNA vaccine development and production. Raw materials critical to plasmid and linear DNA production-specialized enzymes, chromatography resins, single-use bioprocess components, and reagent-grade consumables-are sensitive to cross-border cost fluctuations. Where tariffs have increased input prices or created greater procurement uncertainty, sponsors and contract development and manufacturing organizations have responded by reassessing sourcing strategies, extending inventory buffers, and pursuing localized supplier relationships to stabilize lead times.

These adjustments have practical downstream effects on program timelines and contracting practices. Developers are prioritizing dual-sourcing strategies, qualifying domestic manufacturing partners where feasible, and incorporating tariff contingencies into procurement contracts and milestone planning. Regulatory engagement has become more prominent as companies navigate import documentation, classification disputes, and compliance with evolving trade policies. At the same time, the trade environment has prompted more deliberate capital allocation toward regional manufacturing capabilities and supply-chain resilience initiatives, particularly for entities that view long-term commercial supply as a strategic differentiator rather than a short-term cost issue.

Key segmentation insights illuminating how application focus, platform choice, delivery modality, clinical stage, and end-user dynamics inform program strategy and commercialization planning

Segmentation-driven insights reveal distinct development pathways and commercial considerations across applications, technology platforms, delivery methods, administration routes, development stages, and end users. On the application axis, programs targeting infectious diseases-subdivided into bacterial infections, parasitic diseases, and viral infections-tend to emphasize rapid immune induction, cold-chain resilience, and scalability, while oncology programs focusing on hematological malignancies and solid tumors prioritize antigen specificity, combination immunotherapy strategies, and tumor microenvironment modulation. Platform selection-whether linear DNA, minicircle DNA, or plasmid DNA-shapes manufacturing complexity, payload capacity, and perceptions of genomic safety, influencing both regulatory dialogue and partner selection.

Delivery modalities exert a decisive influence on clinical strategy and patient experience. Electroporation has proven effective for enhancing transfection rates and is commonly paired with intramuscular or intradermal administration to maximize antigen expression, while gene gun approaches and nanoparticle delivery are being optimized to improve tolerability and enable mucosal routes such as intranasal delivery. Needle injection remains a pragmatic option in many clinical settings. Development stage segmentation, which spans preclinical to clinical phases I through III and commercial readiness, dictates different evidence requirements, investment profiles, and partnership models. Finally, the end-user landscape-comprising clinics, hospitals, and research institutions-drives considerations around ease of administration, on-site infrastructure needs, and training requirements, factors that are particularly salient when planning rollouts or pilot implementation studies.

Actionable regional insights that explain how regulatory, manufacturing, and healthcare system differences across the Americas, Europe Middle East & Africa, and Asia-Pacific direct program strategies

Regional perspectives shape strategic priorities for developers and investors across markets with differing regulatory frameworks, healthcare infrastructure, and manufacturing capacity. In the Americas, strong capital markets and an innovation-oriented regulatory environment encourage early-stage trials and public-private partnerships, while concentrated manufacturing clusters support rapid scale-up capabilities and vertically integrated supply chains. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with varied access pathways and procurement mechanisms, prompting sponsors to adopt flexible clinical development plans and payer engagement strategies that reflect local reimbursement realities.

The Asia-Pacific region is characterized by dense manufacturing infrastructure, growing biotech ecosystems, and high-priority public health agendas that favor expedited adoption for vaccines demonstrating clear benefit. These regional attributes influence decisions about clinical trial localization, licensing strategies, and manufacturing siting. As a result, stakeholders are increasingly adopting regionally tailored approaches that align trial designs, regulatory submissions, and market access plans with local norms while preserving global program coherence. Transitioning smoothly across regions requires early cross-jurisdictional regulatory planning and strategic partnerships that can bridge technical, logistical, and policy gaps.

Critical company-level insights describing how platform innovators, clinical biotechs, large pharma partners, and CDMOs are aligning capabilities to accelerate DNA vaccine progress

The competitive and collaborative makeup of companies active in the DNA vaccine space spans specialist platform developers, clinical-stage biotechs, large pharmaceutical partners, and contract manufacturing organizations. Platform developers are differentiating through molecular design, proprietary delivery adjuncts, or manufacturing process innovations intended to reduce cost of goods and improve expression efficiency. Clinical-stage biotechs often focus on narrowly defined indications where a differentiated immunologic profile or compendium of biomarkers can accelerate proof-of-concept, while larger pharmaceutical firms tend to pursue strategic alliances or licensing arrangements to complement existing vaccine portfolios and distribution capabilities.

Contract development and manufacturing organizations play a pivotal role by offering scale, regulatory experience, and process optimization services that de-risk late-stage programs. Academic institutions and translational research centers also contribute through early-stage validation, platform refinement, and investigator-initiated trials. Across these organizational types, successful players balance technical depth with commercial pragmatism, invest in delivery and administration innovations, and cultivate regulatory engagement to smooth path-to-market barriers. Strategic collaborations that bring together complementary capabilities-such as combining a novel platform with an experienced clinical development partner and a CDMO capable of GMP supply-are increasingly the dominant route to de-risked advancement and broader clinical adoption.

Actionable recommendations for industry leaders to prioritize delivery innovation, supply-chain resilience, regulatory strategy, collaborative partnerships, and tailored commercialization playbooks

Industry leaders can adopt a set of pragmatic, high-impact actions to accelerate development and commercial readiness while mitigating risk. First, prioritize investment in delivery technologies and administration pathways that demonstrate reproducible improvements in antigen expression and patient tolerability, aligning these investments with target indication characteristics and end-user needs. Second, strengthen supply-chain resilience by qualifying multiple suppliers, exploring regional manufacturing partnerships, and embedding tariff and trade contingencies into procurement strategies to avoid program interruptions and protect timelines.

Third, pursue modular regulatory engagement and adaptive clinical designs that emphasize biomarker-driven endpoints and immune correlates, thereby reducing uncertainty and enabling faster go/no-go decisions. Fourth, cultivate cross-sector collaborations that pair molecular platform expertise with clinical development capability and scalable manufacturing to create end-to-end value chains. Finally, develop tailored commercialization playbooks that reflect regional regulatory norms, reimbursement pathways, and infrastructure constraints, and invest in training and administration support to ensure smooth deployment in clinics and hospitals. Together these actions create a defensible pathway from proof-of-concept through sustainable market access.

Research methodology describing the integrated approach of literature synthesis, regulatory review, expert consultations, and supply-chain analysis that underpins the findings

The research underlying this executive-level analysis combined a structured review of peer-reviewed literature, clinical trial registries, regulatory guidance documents, and publicly available technical reports with targeted expert consultations. Scientific and clinical inputs were triangulated to ensure consistency across preclinical validation, delivery modality performance, and clinical development patterns. Trade and policy impacts were assessed through analysis of recent tariff schedules, public trade notices, and supply-chain disruption case studies, with attention to how procurement and manufacturing decisions are adapting in real time.

Qualitative interviews with developers, contract manufacturers, clinical investigators, and regulatory advisors provided context on operational bottlenecks, technology adoption drivers, and preferred partnership archetypes. Throughout the study, findings were cross-checked for technical accuracy and relevance, and conclusions emphasized actionable implications over speculative forecasting. The methodological approach prioritized transparency, reproducibility, and the integration of technical, clinical, and commercial perspectives to produce a synthesis that supports strategic decision-making across stakeholders engaged in the DNA vaccine ecosystem.

Conclusion synthesizing technological progress, operational imperatives, and regional considerations that collectively define the path to DNA vaccine impact

In conclusion, DNA vaccines are transitioning from a primarily theoretical promise to a pragmatic element of contemporary immunotherapy and prophylactic strategies. Advances in platform engineering, coupled with meaningful improvements in delivery methods and administration practices, are expanding the set of indications where DNA vaccines can be competitively positioned. At the same time, external factors such as trade policy dynamics and diverse regional environments require deliberate planning around manufacturing, sourcing, and market-entry strategies.

For stakeholders, success depends on aligning scientific differentiation with operational excellence and regulatory foresight. Those who invest early in delivery optimization, supply-chain resilience, and collaborative partnership models will be positioned to convert technical promise into clinical impact and, ultimately, sustainable adoption. The pathway forward emphasizes targeted, evidence-driven development programs that are regionally informed and operationally pragmatic, enabling DNA vaccines to play a meaningful role in both infectious disease control and oncology care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Advancements in nanoparticle and electroporation delivery systems for DNA vaccines improving immunogenicity in clinical trials
• 5.2. Rising investment from government and private funds fueling accelerated DNA vaccine platform research and commercialization
• 5.3. Development of thermostable plasmid formulations reducing cold chain dependency for global DNA vaccine distribution
• 5.4. Emergence of personalized cancer DNA vaccines utilizing neoantigen identification and high throughput sequencing technologies
• 5.5. Strategic licensing agreements between biotech innovators and major pharma accelerating DNA vaccine pipeline expansions
• 5.6. Regulatory approval milestones for human DNA vaccine candidates against emerging infectious diseases in key markets
• 5.7. Integration of advanced adjuvant systems with plasmid DNA constructs enhancing cellular and humoral immune responses
• 5.8. Scale up of industrial plasmid manufacturing processes to meet growing global demand for DNA vaccine clinical trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Vaccine Market, by Application

• 8.1. Infectious Diseases
  • 8.1.1. Bacterial Infections
  • 8.1.2. Parasitic Diseases
  • 8.1.3. Viral Infections
• 8.2. Oncology
  • 8.2.1. Hematological Malignancies
  • 8.2.2. Solid Tumors

9. DNA Vaccine Market, by Technology Platform

• 9.1. Linear DNA
• 9.2. Minicircle DNA
• 9.3. Plasmid DNA

10. DNA Vaccine Market, by Delivery Method

• 10.1. Electroporation
• 10.2. Gene Gun
• 10.3. Nanoparticle Delivery
• 10.4. Needle Injection

11. DNA Vaccine Market, by Administration Route

• 11.1. Intradermal
• 11.2. Intramuscular
• 11.3. Intranasal
• 11.4. Subcutaneous

12. DNA Vaccine Market, by Development Stage

• 12.1. Clinical Phase I
• 12.2. Clinical Phase II
• 12.3. Clinical Phase III
• 12.4. Commercial
• 12.5. Preclinical

13. DNA Vaccine Market, by End User

• 13.1. Clinics
• 13.2. Hospitals
• 13.3. Research Institutions

14. DNA Vaccine Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. DNA Vaccine Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. DNA Vaccine Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Inovio Pharmaceuticals, Inc.
  • 17.3.2. GeneOne Life Science, Inc.
  • 17.3.3. VGXI, Inc.
  • 17.3.4. Zydus Cadila Ltd.
  • 17.3.5. GenScript Biotech Corporation
  • 17.3.6. Applied DNA Sciences, Inc.
  • 17.3.7. Entos Pharmaceuticals, Inc.
  • 17.3.8. Takis Biotech S.r.l.
  • 17.3.9. Vical, Inc.
  • 17.3.10. Merck & Co., Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS DNA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. DNA VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DNA VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DNA VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. AMERICAS DNA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 180. AMERICAS DNA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 181. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 182. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 183. AMERICAS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 184. AMERICAS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 185. AMERICAS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 187. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 188. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 197. NORTH AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. NORTH AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. NORTH AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 200. NORTH AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 201. NORTH AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 202. NORTH AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 203. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 204. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 205. NORTH AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 206. NORTH AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 207. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 208. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 209. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 210. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 215. LATIN AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. LATIN AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. LATIN AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 218. LATIN AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 219. LATIN AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 220. LATIN AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 221. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 222. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 223. LATIN AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 224. LATIN AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 225. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 226. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 227. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 228. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 229. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 230. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 231. LATIN AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 232. LATIN AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. EUROPE DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. EUROPE DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. EUROPE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 254. EUROPE DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 255. EUROPE DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 269. MIDDLE EAST DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. MIDDLE EAST DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. MIDDLE EAST DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 272. MIDDLE EAST DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 273. MIDDLE EAST DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 274. MIDDLE EAST DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 275. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 276. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 277. MIDDLE EAST DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 278. MIDDLE EAST DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 279. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 280. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 281. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 282. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 283. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 284. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 285. MIDDLE EAST DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 286. MIDDLE EAST DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 287. AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 288. AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 289. AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 290. AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 291. AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 292. AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 293. AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 294. AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 295. AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 296. AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 297. AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 298. AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 299. AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 300. AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 301. AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 302. AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 303. AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 304. AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 305. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 306. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 307. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 308. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 309. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 310. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 311. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 312. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 313. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 314. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 315. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 316. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 317. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 318. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 319. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 320. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 321. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 322. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 323. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 324. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 325. ASEAN DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 326. ASEAN DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 327. ASEAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 328. ASEAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 329. ASEAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 330. ASEAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 331. ASEAN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 332. ASEAN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 333. ASEAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 334. ASEAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 335. ASEAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 336. ASEAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 337. ASEAN DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
• TABLE 338. ASEAN DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
• TABLE 339. ASEAN DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
• TABLE 340. ASEAN DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
• TABLE 341. ASEAN DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 342. ASEAN DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 343. GCC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 344. GCC DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 345. GCC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 346. GCC DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 347. GCC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 348. GCC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 349. GCC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 350. GCC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 351. GCC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 352. GCC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 353. GCC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 354. GCC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 355. GCC D